Malignancies in systemic lupus erythematosus

Mruganka Kale, Rosalind Ramsey-Goldman, Caroline Gordon, Ann E. Clarke, Sasha Bernatsky*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

The purpose of this review is to underline important advancements in the understanding of cancer risks in systemic lupus erythematosus (SLE). In SLE, there is an increased risk of specific kinds of malignancy. For example, the risk of non-Hodgkin's lymphoma is increased several-fold in SLE versus the general population. In addition, heightened risks for lung cancer, thyroid cancer and cervical dysplasia in SLE have been found. Some have postulated that immunosuppressive drugs play a role, as well as other important mediators, such as lupus disease activity itself. One new frontier being explored is the significant finding of a decreased risk of certain nonhematologic cancers (e.g., breast, ovarian, endometrial and prostate) in SLE. The reasons for this are currently under study.

Original languageEnglish (US)
Pages (from-to)275-280
Number of pages6
JournalInternational Journal of Clinical Rheumatology
Volume8
Issue number2
DOIs
StatePublished - Apr 1 2013

Keywords

  • cancer
  • immunosuppressive drug
  • malignancy
  • risk
  • systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Malignancies in systemic lupus erythematosus'. Together they form a unique fingerprint.

Cite this